Trial Profile
An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2010/2011, in an Adult and Elderly Population.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2020
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Ology Bioservices
- 23 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jul 2010 New trial record